S100A9 and metabolic dysfunction-associated steatohepatitis: Indeed, S100A8 and S100A9 are upregulated in the adipose tissue samples of NASH patients and CXCL1-induced experimental NASH models, and the administration of paquinimod, a S100A9 inhibitor, attenuated the CXCL1-induced NASH in mice (128).